Seegene, Korean provider to develop molecular diagnostics for cancer
Seegene has entered a partnership with Samsung Medical Center to co-develop molecular diagnostics for cancer.
In this partnership, Seegene will bring its molecular diagnostic technology and Samsung will offer its clinical and disease pathology expertise to the development of new cancer molecular diagnostics tests. Samsung will also provide the first test sites, according to Seegene, which is based in Seoul, Korea.
Seegene will develop new tests for drug resistance and Single Nucleotide Polymorphism (SNP) based on multiplex PCR technology and real-time PCR technology, which will detect genetic mutations indicative of certain cancers. The initial tests to be developed will be for nonsmall cell lung cancer, colon cancer, pancreatic cancer and cholangiocarcinoma.
Oncologists will use these new molecular diagnostic tests to determine the genomic profile of a patient's tumor to understand if the patient is likely to respond to cancer therapies, such as tamoxifen or chemotherapy, or if the cancer will return or metastasize, added the company.
In this partnership, Seegene will bring its molecular diagnostic technology and Samsung will offer its clinical and disease pathology expertise to the development of new cancer molecular diagnostics tests. Samsung will also provide the first test sites, according to Seegene, which is based in Seoul, Korea.
Seegene will develop new tests for drug resistance and Single Nucleotide Polymorphism (SNP) based on multiplex PCR technology and real-time PCR technology, which will detect genetic mutations indicative of certain cancers. The initial tests to be developed will be for nonsmall cell lung cancer, colon cancer, pancreatic cancer and cholangiocarcinoma.
Oncologists will use these new molecular diagnostic tests to determine the genomic profile of a patient's tumor to understand if the patient is likely to respond to cancer therapies, such as tamoxifen or chemotherapy, or if the cancer will return or metastasize, added the company.